Vital: Vanguard Investigations of Therapeutic Approaches to Lung Cancer

Abstract

The VITAL Research Program will provide a better understanding of the cellular and molecular processes that drive lung tumorigenesis so that an accurate risk model for recurrence and/or the development of the second primary tumor can be developed, and the biologic agents most effect in reducing these events in the group of high-risk patients can be identified. Until this time, our clinical trails (Vanguard and Celecoxib trials) are ongoing and Tarceva trial will be opened in January 2007. The research projects are proceeding well as proposed, producing valuable findings with cell lines, and will validate these results using the clinical samples obtained from the VITAL trials in the coming years.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2007
Accession Number
ADA469431

Entities

People

  • David M Stewart
  • Reuben Lotan
  • Waun K. Hong

Organizations

  • University of Texas at Austin

Tags

DTIC Thesaurus Topics

  • Cell Physiological Processes
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Medical Personnel

Fields of Study

  • Medicine

Readers

  • Molecular and genetic basis of cancer.
  • Oncology (Cancer Research).
  • Technical Research and Report Writing.